2022
Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy
Mittendorf EA, Kantor O, Weiss A, Richardson E, Garrido-Castro A, Portnow LH, Krop IE, Lin NU, Winer EP, Tolaney SM, King TA. Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy. Annals Of Surgical Oncology 2022, 30: 100-106. PMID: 35941343, DOI: 10.1245/s10434-022-12357-8.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNational Cancer DatabaseNormal clinical examinationAxillary ultrasoundNegative clinical examinationClinical examinationUpfront surgeryCT2 tumorsInstitutional databaseBreast cancerEarly-stage triple-negative breast cancerStage triple-negative breast cancerAddition of immunotherapyNodal positivity ratePathologic nodal statusNode-positive patientsEvent-free survivalNode-positive diseaseRisk-benefit ratioCT1-2N0NCDB cohortPreoperative immunotherapyResultsFor patientsPositive nodesPreoperative chemotherapy
2020
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center
Losk K, Freedman RA, Laws A, Kantor O, Mittendorf EA, Tan-Wasielewski Z, Trippa L, Lin NU, Winer EP, King TA. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Research And Treatment 2020, 185: 215-227. PMID: 32939592, DOI: 10.1007/s10549-020-05931-9.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalPN1 breast cancerRecurrence scoreChemotherapy useBreast cancerOverall survivalChemotherapy receiptPN1 patientsRS testingUse of RSNode-positive breast cancerOncotype DX recurrence scoreAdjuvant chemotherapy receiptLow genomic riskNode-positive diseaseAdjuvant treatment decisionsLow recurrence scoreShort-term outcomesMultivariate logistic regressionComprehensive cancer centerDX recurrence scoreOncotype DX testingChemotherapy omissionPT1-2N0Upfront surgeryExpanding criteria for prognostic stage IA disease in HR+ breast cancer.
Kantor O, King T, Shak S, Russell C, Giuliano A, Hortobagyi G, Burstein H, Winer E, Sparano J, Mittendorf E. Expanding criteria for prognostic stage IA disease in HR+ breast cancer. Journal Of Clinical Oncology 2020, 38: 550-550. DOI: 10.1200/jco.2020.38.15_suppl.550.Peer-Reviewed Original ResearchStage IA diseaseRecurrence scoreIA diseaseN categoryOncotype DX recurrence scoreNode-positive diseaseAJCC staging systemDX recurrence scoreRS resultsRS 11Median followDSS ratesPositive diseaseSEER databaseReceptor statusStaging systemEvidence of utilityScore 11Breast cancerTrial dataDiseaseAdditional studiesPatientsStagingDSS
2019
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Jakubowski DM, Russell C, Winer EP, Partridge AH. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. Journal Of Clinical Oncology 2019, 38: 725-733. PMID: 31809240, PMCID: PMC7048163, DOI: 10.1200/jco.19.01959.Peer-Reviewed Original ResearchConceptsNode-positive breast cancerDistant recurrence-free survivalRecurrence scoreBreast cancerBreast Cancer StudyN0 diseaseN1 diseaseYoung womenYoung Women's Breast Cancer StudyPositive/HER2-negative breast cancerHER2-negative breast cancerHuman epidermal growth factor receptorEarly distant recurrenceEarly-stage estrogenN0 breast cancerRS risk groupsNode-positive diseaseMinority of patientsRecurrence-free survivalYears of ageEpidermal growth factor receptorGrowth factor receptorDistant recurrenceAxillary nodesEligible women
2017
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)
Ollila DW, Cirrincione CT, Berry DA, Carey LA, Sikov WM, Hudis CA, Winer EP, Golshan M. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). Journal Of The American College Of Surgeons 2017, 224: 688-694. PMID: 28089784, PMCID: PMC5616181, DOI: 10.1016/j.jamcollsurg.2016.12.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAxillaBiopsyBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularFemaleHumansLymph Node ExcisionLymph NodesLymphatic MetastasisMastectomyMiddle AgedNeoadjuvant TherapyNeoplasm StagingPractice Patterns, Physicians'Receptor, ErbB-2Sentinel Lymph Node BiopsyTriple Negative Breast NeoplasmsUnited StatesConceptsAxillary lymph node dissectionNeoadjuvant systemic therapyNode-positive patientsSentinel node biopsyStage II/III breast cancerResidual axillary diseaseNode biopsyAxillary diseaseSystemic therapyBreast cancerAxillary node evaluationAxillary surgical proceduresPathologic nodal statusLymph node dissectionNode-positive diseaseCore needle biopsyFine-needle aspirationAxillary evaluationAxillary managementCALGB 40601N0 diseaseAxillary procedureNode dissectionRadiologic stagingNodal status
2015
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H, Members P, André F, Baselga J, Bergh J, Bonnefoi H, Burstein H, Cardoso F, Castiglione-Gertsch M, Coates A, Colleoni M, Curigliano G, Davidson N, Di Leo A, Ejlertsen B, Forbes J, Galimberti V, Gelber R, Gnant M, Goldhirsch A, Goodwin P, Harbeck N, Hayes D, Huober J, Hudis C, Ingle J, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne C, Partridge A, de la Peña L, Piccart-Gebhart M, Pritchard K, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Thürlimann B, Toi M, Tutt A, Viale G, von Minckwitz G, Watanabe T, Whelan T, Winer E, Xu B. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals Of Oncology 2015, 26: 1533-1546. PMID: 25939896, PMCID: PMC4511219, DOI: 10.1093/annonc/mdv221.Peer-Reviewed Original ResearchMeSH KeywordsAnthracyclinesAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAxillaBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularChemotherapy, AdjuvantFemaleHumansLymph Node ExcisionMastectomyMastectomy, SegmentalNeoplasm StagingPlatinum CompoundsPractice Guidelines as TopicRadiotherapy, AdjuvantReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTamoxifenTaxoidsTrastuzumabConceptsEarly breast cancerLuminal diseaseBreast cancerSt Gallen International Breast Cancer ConferenceSt Gallen International Expert ConsensusNew breast cancer casesPanel recommendationsEndocrine-responsive diseaseHER2-positive diseaseOvarian function suppressionNode-positive diseaseBreast cancer deathsER-negative diseaseTreatment of patientsAnnals of OncologyNode-negative cancersPremature ovarian failureBreast cancer casesSubstantial new evidenceInternational expert consensusPremenopausal patientsSimplified regimenAdjuvant therapyAxillary dissectionPremenopausal women
2012
Quality of Life in Long-Term Survivors of Metastatic Breast Cancer
Meisel JL, Domchek SM, Vonderheide RH, Giobbie-Hurder A, Lin NU, Winer EP, Partridge AH. Quality of Life in Long-Term Survivors of Metastatic Breast Cancer. Clinical Breast Cancer 2012, 12: 119-126. PMID: 22444718, DOI: 10.1016/j.clbc.2012.01.010.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerHormone receptor-positive diseaseNode-positive diseaseCancer Therapy-BreastLong-term survivorsSubset of womenHADS anxiety scoreHADS depression scorePopulation of womenFunctional Social Support QuestionnaireFisher's exact testQuality of lifeWilcoxon rank sum testCross-sectional surveyIES-R scaleRank sum testNorth Carolina Functional Social Support QuestionnaireAdjuvant therapyEligible womenPositive diseaseSpearman correlation coefficientDisease characteristicsHospital AnxietyMedical history